Vivtex
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
135 William T Morrissey Blvd Ste P101, B...Phone Number
(617) 863-3650Website
www.vivtex.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
2
1
1
About Vivtex
Vivtex strives to transform drug development using a new platform technology called gastrointestinal tract organ robotic interface system (GI-ORIS) that enables robotic screening with fully intact and functional organs. GI-ORIS technology was developed in the Langer lab at MIT and can be used for various applications (e.g. oral delivery of biologics, drug toxicity mitigation, spatial and temporal drug delivery). Vivtex leverages these unique capabilities of the GI-ORIS to develop new oral therapeutics. Vivtex's mission is to serve patients by increasing the efficacy, safety and adherence of existing and novel therapies. The company is in preclinical stage and has multiple drug development programs including reformulations of existing drugs as well as new chemical entities. The company was co-founded by Professor Robert Langer (MIT), Dr. Giovanni Traverso (Harvard Medical School), Doug Eby (Cambridge Science), and Thomas von Erlach.Explore more
Vivtex Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Vivtex your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Vivtex had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Vivtex
Vivtex, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Vivtex launches new products
Funding: Get notified immidiatlly once Vivtex has new funding data
Check if Vivtex has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Vivtex is spiking on competitors!
Earning: See what the market has to say on Vivtex recently announced quarterly report
Recommended Actions
Find VP level buyers at Vivtex
Find more new buyers
Compare Similar Companies to Vivtex
Compare insights from companies similar to Vivtex, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Vivtex is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Vivtex is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Vivtex.
Vivtex Tech Stack
A closer look at the technologies used by Vivtex
Most Recent Scoops
Event
Person-Based
Partnership, Events, Product Development, Pharmaceuticals, Podcast
Executive Move
Board of Directors
Promotion
Executive Move
Promotion
Executive Move
Vivtex News & Media
Novo Nordisk and Vivtex collaborate for oral medicines development
Vivtex is set to receive research funding, upfront payments, milestone payments up to $2.1bn, and tiered royalties.Novo Nordisk and Vivtex partner to develop next-generation oral medicines for obesity and diabetes
Novo Nordisk and Vivtex Corp announced partnership to develop next-generation oral biologic medicines for obesity, diabetes + associated comorbiditiesOrbis Medicines and Vivtex Form Research & Exclusive Licensing Collaboration to Support Orbis Development of Next-Generation Orally Dosable ‘nCycles’
COPENHAGEN--(BUSINESS WIRE)--Orbis Medicines and Vivtex today announced a research collaboration and option to an exclusive license.Vivtex Enters New Research Agreement with Equillium to Develop GI-targeted Formulations for its First-in-Class Oral, Bi-Specific Peptide Therapy
Cambridge, MA, USA and Schlieren, Switzerland – September 16, 2024. Vivtex Corporation (“Vivtex” or “the Company”), a biotech company aiming to transform the development of oral biologic therapies for major diseases, announces that it has entered a research and licensing agreement with Equillium, Inc. (“Equillium”), a clinical-stage biotechnology company developing novel therapeutics to treat severe autoimmune and inflammatory disorders.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Vivtex
Sign Up For FreeTo access detailed company insights
Vivtex strives to transform drug development using a new platform technology called gastrointestinal tract organ robotic interface system (GI-ORIS) that enables robotic screening with fully intact and functional organs. GI-ORIS technology was developed in the Langer lab at MIT and can be used for various applications (e.g. oral delivery of biologic... Read More
